比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元

Group 1 - AgomAb Therapeutics, a Belgian biotech company, announced its IPO terms, planning to issue 12.5 million shares at a price range of $15 to $17 per share, aiming to raise $200 million [1][2] - The company focuses on developing TGFβ inhibitors for Crohn's disease and other fibrotic diseases, with a fully diluted market capitalization projected to reach $875 million based on the midpoint of the proposed price range [1] - The lead candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor targeting ALK5 (TGFβR1), primarily aimed at treating fibrotic stricturing Crohn's disease (FSCD) [1] Group 2 - Another clinical-stage candidate, AGMB-447, is an inhaled ALK5 small molecule inhibitor for treating idiopathic pulmonary fibrosis (IPF) [2] - The company also has a preclinical candidate, a monoclonal antibody targeting liver cirrhosis, and has completed the necessary studies for new drug clinical trial applications [2] - AgomAb Therapeutics was founded in 2017 and plans to list on NASDAQ under the ticker "AGMB," with the IPO expected to be priced in February of this year [2]